Jennifer Crosby
Family · Houston, TXNPI 1548301310
Payments from drug & device makers
Across 478 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Lilly USA, LLC$830
- Novo Nordisk$782
- Boehringer Ingelheim$671
- AstraZeneca$528
- Abbott$458
- plus $4K from 49 others
What the payments were for
- Food & beverage$8,178100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$122
How this compares
$8,178 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $105,533 |
| JardianceEmpagliflozin | 70 | $80,364 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $22,772 |
| FarxigaDapagliflozin Propanediol | 18 | $17,933 |
| MounjaroTirzepatide | 13 | $13,127 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 41 | $13,048 |
| MyrbetriqMirabegron | 13 | $12,082 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 30 | $9,056 |
| LinzessLinaclotide | 12 | $7,124 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 31 | $6,843 |
| VascepaIcosapent Ethyl | 11 | $5,398 |
| Levothyroxine Sodium | 251 | $2,696 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 31 | $2,157 |
| Rosuvastatin Calcium | 163 | $1,984 |
| SynthroidLevothyroxine Sodium | 21 | $1,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $782 | $105,53399 claims |
| Boehringer IngelheimJardiance | $671 | $80,36470 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $1,060 | $38,67196 claims |
| AstraZenecaFarxiga | $528 | $17,93318 claims |
| Lilly USA, LLCMounjaro | $830 | $13,12713 claims |
| PfizerAbrysvo | $299 | $13,04841 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $12,08213 claims |
| AbbVieLinzess, Synthroid | $449 | $8,89733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.